Fein Seymour Howard 4

What Happened Fein Seymour Howard, the company's CRO/CMO, was granted 250 restricted stock units (RSUs) on July 10, 2026. The award was reported as an acquisition at $0.00 (transaction code A — award/grant). Each RSU will be settled by delivery of one share of the issuer's Series A Convertible Preferred Stock; each Series A preferred is convertible into 1,000 shares of Oncotelic common stock, so the full grant could represent a contingent entitlement to 250,000 common shares after settlement and conversion.

Key Details

• Transaction date: July 10, 2026; Form 4 filed July 23, 2026 (filed late relative to the typical 2-business-day Form 4 deadline).
• Reported consideration: $0.00 (grant of 250 RSUs).
• Vesting conditions: RSUs vest upon (a) uplisting of the common stock to a national securities exchange on or before June 30, 2027 (or later if the board approves) and (b) the reporting person’s continued service for six months following the uplisting.
• Shares owned after transaction: Not specified in the filing.
• Transaction type/code: A = Award/Grant of derivative securities (RSUs).
• Footnote highlights: Each RSU converts to one Series A preferred share; each Series A preferred is convertible into 1,000 common shares.

Context This is a derivative award subject to performance (uplisting) and time-based vesting — not an immediate purchase or sale of common stock. Such grants are common for executive compensation and do not by themselves indicate current buying/selling of common shares. Note the late filing could be an administrative oversight; late Form 4s reduce the speed at which investors can assess insider activity.